[Current treatment of hemophilia B].
Tusell
J M
JM
Unitat d'Hemofília, Hospitals Vall d'Hebron.
D000818:Animals; D016466:CHO Cells; D003362:Cost-Benefit Analysis; D006224:Cricetinae; D003412:Cricetulus; D004340:Drug Contamination; D005164:Factor IX / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D002836:Hemophilia B / Q000191:economics / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007518:Isoantibodies / Q000096:biosynthesis; D011516:Prothrombin / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use; D013927:Thrombosis / Q000139:chemically induced; D014162:Transfection; D014777:Virus Diseases / Q000635:transmission
D007518:Isoantibodies; D011993:Recombinant Fusion Proteins; D011516:Prothrombin; D005164:Factor IX